夜尿症治療薬の世界市場レポート 2025年

夜尿症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.1％で21億6,000万米ドルに成長します。予測期間中に予想される成長は、小児のストレス関連膀胱機能障害の増加、精神的外傷後の二次性遺尿症例の増加、小児ヘルスケアを促進する政府の取り組み、遠隔診断・治療のための遠隔医療の成長、薬剤へのアクセス性を高めるe薬局の台頭などの要因によってもたらされます。予測期間における主な動向としては、薬剤製剤の進歩、ドラッグデリバリー法の開発、新規治療薬の承認、併用療法の人気の高まり、AIと精密医療による薬剤開発期間の短縮などが挙げられます。

個別化医療に対する需要の高まりが、今後の夜尿症治療薬市場の成長を牽引すると予想されます。個別化医療は、治療やヘルスケア戦略を個人固有の遺伝子プロファイル、ライフスタイル、嗜好、特定の健康状態に合わせて調整することで、より効果的な結果を導くものです。このような需要の増加は、医療技術の進歩により、医療提供者が各患者の遺伝的体質や健康状態に基づいて治療をカスタマイズできるようになり、その結果、より的を絞った効果的な治療が可能になったことが背景にあります。夜尿症治療薬の場合、個別化医療とは、患者の病歴や根本的な原因に応じて治療計画をカスタマイズし、治療の効果とアドヒアランスの両方を向上させることです。例えば、2024年2月、個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者向けに16の新しい個別化治療を承認し、2022年の6から増加したと報告しました。その結果、個別化医療の需要が夜尿症治療薬市場の成長を後押ししています。

ヘルスケア支出の増加は、今後数年間の夜尿症治療薬市場の成長に寄与すると予想されます。ヘルスケア支出とは、特定期間における個人、政府、組織による医療サービス、製品、公衆衛生への総支出を指します。ヘルスケア支出の増加は、継続的な管理と治療を必要とする慢性疾患の蔓延が進み、薬や専門的なケアにかかる費用が増加することなどが要因となっています。医療費の増加は、研究開発への投資を増やし、先進的な治療法へのアクセスを提供することで、患者に対するケアの有効性と可用性を高め、夜尿症治療薬を支えています。例えば、Peterson-KFF Health System Trackerによれば、米国の医療費は2024年には4兆9,000億米ドルに達し、2023年の4兆6,700億米ドルから5％増加すると予測されています。したがって、ヘルスケア支出の増加が夜尿症治療薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の夜尿症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の夜尿症治療薬市場：成長率分析
• 世界の夜尿症治療薬市場の実績：規模と成長, 2019-2024
• 世界の夜尿症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の夜尿症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の夜尿症治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デスモプレシン
• イミプラミン
• オキシブチニン
• 併用薬物療法
• 抗うつ薬
• 世界の夜尿症治療薬市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子供
• 青少年
• 成人
• 高齢者
• 世界の夜尿症治療薬市場：処方タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• 液体ソリューション
• スプレー
• パッチ
• 徐放性製剤
• 世界の夜尿症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の夜尿症治療薬市場：デスモプレシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 鼻スプレー
• 舌下錠
• 世界の夜尿症治療薬市場：イミプラミンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 徐放性カプセル
• 世界の夜尿症治療薬市場：オキシブチニンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放錠
• 徐放錠
• 経皮パッチ
• シロップ
• 世界の夜尿症治療薬市場：併用薬物療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デスモプレシンとオキシブチニン
• デスモプレシンとイミプラミン
• オキシブチニンとイミプラミン
• 世界の夜尿症治療薬市場：抗うつ薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 三環系抗うつ薬
• 選択的セロトニン再取り込み阻害薬（SSRI）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）

第7章 地域別・国別分析

• 世界の夜尿症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の夜尿症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 夜尿症治療薬市場：競合情勢
• 夜尿症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Willmar Schwabe GmbH & Co. KG Overview, Products and Services, Strategy and Financial Analysis
  • Ferring Pharmaceuticals A/S Overview, Products and Services, Strategy and Financial Analysis
  • UroGen Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bakson Drugs and Pharmaceuticals Pvt. Ltd.
• Nordic Pharma Group
• Dr. Reckeweg & Co. GmbH
• Chummie
• Taiho Pharmaceutical Co. Ltd.
• AA Pharma Inc.
• Bakson Drugs and Pharmaceuticals Pvt. Ltd.
• Aark Pharmaceuticals Ltd.
• Alturix Ltd.
• Wellesley Pharmaceuticals LLC
• German Homoeo Care and Cure Pvt. Ltd.
• Laboratoires Ledoux Reflexe Inc.
• Global Continence Inc.
• Serenity Pharmaceuticals LLC
• Vantia Therapeutics Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 夜尿症治療薬市場2029：新たな機会を提供する国
• 夜尿症治療薬市場2029：新たな機会を提供するセグメント
• 夜尿症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Nocturnal enuresis medication refers to drugs designed to treat and alleviate involuntary urination during sleep, commonly known as bedwetting, which affects both children and, in some cases, adults. The primary aim is to improve bladder control, reduce the amount of urine produced overnight, or modify the body's natural sleep response to a full bladder.

The main classes of drugs used for nocturnal enuresis include desmopressin, imipramine, oxybutynin, combined pharmacotherapy, and antidepressants. Desmopressin is a synthetic hormone that helps reduce nighttime urine production and is often prescribed for treating nocturnal enuresis (bedwetting). It is suitable for various age groups, including children, adolescents, adults, and the elderly, and comes in multiple forms such as tablets, liquid solutions, sprays, patches, and extended-release formulations. These medications are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The nocturnal enuresis medication market research report is one of a series of new reports from The Business Research Company that provides nocturnal enuresis medication market statistics, including nocturnal enuresis medication industry global market size, regional shares, competitors with a nocturnal enuresis medication market share, detailed nocturnal enuresis medication market segments, market trends and opportunities, and any further data you may need to thrive in the nocturnal enuresis medication industry. This nocturnal enuresis medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nocturnal enuresis medication market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historical period can be attributed to the high global prevalence of nocturnal enuresis in children, growing awareness of adult nocturnal enuresis, an increasing pediatric population, higher diagnosis rates due to enhanced screening methods, and a rising incidence of comorbid conditions.

The nocturnal enuresis medication market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The expected growth in the forecast period is driven by factors such as an increase in stress-related bladder dysfunction in children, a rise in secondary enuresis cases following psychological trauma, government initiatives promoting child healthcare, the growth of telemedicine for remote diagnosis and treatment, and the rise of e-pharmacies enhancing drug accessibility. Key trends in the forecast period include advancements in drug formulations, the development of new delivery methods, the approval of new therapeutic agents, the growing popularity of combination therapies, and the acceleration of drug development timelines through AI and precision medicine.

The growing demand for personalized care is expected to drive the growth of the nocturnal enuresis medication market in the future. Personalized care involves tailoring treatments and healthcare strategies to an individual's unique genetic profile, lifestyle, preferences, and specific health conditions, leading to more effective outcomes. This increasing demand is driven by advancements in medical technology that enable healthcare providers to customize treatments based on each patient's genetic makeup and health conditions, resulting in more targeted and effective care. In the case of nocturnal enuresis medication, personalized care involves customizing treatment plans according to a patient's medical history and underlying causes, improving both the effectiveness and adherence to therapy. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. As a result, the demand for personalized care is fueling the growth of the nocturnal enuresis medication market.

Rising healthcare expenditure is expected to contribute to the growth of the nocturnal enuresis medication market in the coming years. Healthcare expenditure refers to the total spending on medical services, products, and public health by individuals, governments, and organizations over a specific period. The increase in healthcare spending is driven by factors such as the growing prevalence of chronic diseases, which require ongoing management and treatment, leading to higher costs for medications and specialized care. The rise in healthcare expenditure supports nocturnal enuresis medication by providing more investment in research, development, and access to advanced treatment options, thereby enhancing the availability and effectiveness of care for patients. For example, the Peterson-KFF Health System Tracker reported that US health spending was projected to reach $4.9 trillion in 2024, a 5% increase from $4.67 trillion in 2023. Therefore, rising healthcare expenditure is boosting the growth of the nocturnal enuresis medication market.

Companies operating in the nocturnal enuresis medication market are focusing on advanced solutions such as orally disintegrating tablets (ODT) to improve patient convenience. Orally disintegrating tablets are solid forms of medication that dissolve quickly in the mouth without the need for water, making them ideal for patients who have difficulty swallowing pills. For example, in March 2024, Adalvo Limited, a pharmaceutical company based in Malta, launched desmopressin orally disintegrating tablets in Europe. This formulation, designed specifically for treating primary nocturnal enuresis, provides a convenient option that disintegrates rapidly in the mouth. It is particularly beneficial for pediatric and elderly patients or those with difficulty swallowing. The launch reflects Adalvo's commitment to offering differentiated pharmaceutical products and improving patient access to essential therapies through strategic partnerships.

Major players in the nocturnal enuresis medication market are Pfizer Inc., Merck & Co. Inc., Dr. Willmar Schwabe GmbH & Co. KG, Ferring Pharmaceuticals A/S, UroGen Pharma Ltd., Bakson Drugs and Pharmaceuticals Pvt. Ltd., Nordic Pharma Group, Dr. Reckeweg & Co. GmbH, Chummie, Taiho Pharmaceutical Co. Ltd., AA Pharma Inc., Bakson Drugs and Pharmaceuticals Pvt. Ltd., Aark Pharmaceuticals Ltd., Alturix Ltd., Wellesley Pharmaceuticals LLC, German Homoeo Care and Cure Pvt. Ltd., Laboratoires Ledoux Reflexe Inc., Global Continence Inc., Serenity Pharmaceuticals LLC, and Vantia Therapeutics Ltd.

North America was the largest region in the nocturnal enuresis medication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nocturnal enuresis medication report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nocturnal enuresis medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nocturnal enuresis medication market consists of sales of fixed-dose combination drugs, nutraceuticals, and herbal supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nocturnal Enuresis Medication Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nocturnal enuresis medication market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nocturnal enuresis medication ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nocturnal enuresis medication market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Desmopressin; Imipramine; Oxybutynin; Combined Pharmacotherapy; Antidepressants
• 2) By Age Group: Children; Adolescents; Adults; Elderly
• 3) By Formulation Type: Tablets; Liquid Solutions; Sprays; Patches; Extended-Release Formulations
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Desmopressin: Oral Tablets; Nasal Sprays; Sublingual Tablets
• 2) By Imipramine: Oral Tablets; Extended-Release Capsules
• 3) By Oxybutynin: Immediate-Release Tablets; Extended-Release Tablets; Transdermal Patches; Syrups
• 4) By Combined Pharmacotherapy: Desmopressin And Oxybutynin; Desmopressin And Imipramine; Oxybutynin And Imipramine
• 5) By Antidepressants: Tricyclic Antidepressants; Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Dr. Willmar Schwabe GmbH & Co. KG; Ferring Pharmaceuticals A/S; UroGen Pharma Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nocturnal Enuresis Medication Market Characteristics

3. Nocturnal Enuresis Medication Market Trends And Strategies

4. Nocturnal Enuresis Medication Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nocturnal Enuresis Medication Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nocturnal Enuresis Medication PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nocturnal Enuresis Medication Market Growth Rate Analysis
• 5.4. Global Nocturnal Enuresis Medication Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nocturnal Enuresis Medication Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nocturnal Enuresis Medication Total Addressable Market (TAM)

6. Nocturnal Enuresis Medication Market Segmentation

• 6.1. Global Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Desmopressin
• Imipramine
• Oxybutynin
• Combined Pharmacotherapy
• Antidepressants
• 6.2. Global Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adolescents
• Adults
• Elderly
• 6.3. Global Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Liquid Solutions
• Sprays
• Patches
• Extended-Release Formulations
• 6.4. Global Nocturnal Enuresis Medication Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Nocturnal Enuresis Medication Market, Sub-Segmentation Of Desmopressin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Nasal Sprays
• Sublingual Tablets
• 6.6. Global Nocturnal Enuresis Medication Market, Sub-Segmentation Of Imipramine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Extended-Release Capsules
• 6.7. Global Nocturnal Enuresis Medication Market, Sub-Segmentation Of Oxybutynin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Tablets
• Extended-Release Tablets
• Transdermal Patches
• Syrups
• 6.8. Global Nocturnal Enuresis Medication Market, Sub-Segmentation Of Combined Pharmacotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Desmopressin And Oxybutynin
• Desmopressin And Imipramine
• Oxybutynin And Imipramine
• 6.9. Global Nocturnal Enuresis Medication Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tricyclic Antidepressants
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

7. Nocturnal Enuresis Medication Market Regional And Country Analysis

• 7.1. Global Nocturnal Enuresis Medication Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nocturnal Enuresis Medication Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nocturnal Enuresis Medication Market

• 8.1. Asia-Pacific Nocturnal Enuresis Medication Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nocturnal Enuresis Medication Market

• 9.1. China Nocturnal Enuresis Medication Market Overview
• 9.2. China Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nocturnal Enuresis Medication Market

• 10.1. India Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nocturnal Enuresis Medication Market

• 11.1. Japan Nocturnal Enuresis Medication Market Overview
• 11.2. Japan Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nocturnal Enuresis Medication Market

• 12.1. Australia Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nocturnal Enuresis Medication Market

• 13.1. Indonesia Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nocturnal Enuresis Medication Market

• 14.1. South Korea Nocturnal Enuresis Medication Market Overview
• 14.2. South Korea Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nocturnal Enuresis Medication Market

• 15.1. Western Europe Nocturnal Enuresis Medication Market Overview
• 15.2. Western Europe Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nocturnal Enuresis Medication Market

• 16.1. UK Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nocturnal Enuresis Medication Market

• 17.1. Germany Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nocturnal Enuresis Medication Market

• 18.1. France Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nocturnal Enuresis Medication Market

• 19.1. Italy Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nocturnal Enuresis Medication Market

• 20.1. Spain Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nocturnal Enuresis Medication Market

• 21.1. Eastern Europe Nocturnal Enuresis Medication Market Overview
• 21.2. Eastern Europe Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nocturnal Enuresis Medication Market

• 22.1. Russia Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nocturnal Enuresis Medication Market

• 23.1. North America Nocturnal Enuresis Medication Market Overview
• 23.2. North America Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nocturnal Enuresis Medication Market

• 24.1. USA Nocturnal Enuresis Medication Market Overview
• 24.2. USA Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nocturnal Enuresis Medication Market

• 25.1. Canada Nocturnal Enuresis Medication Market Overview
• 25.2. Canada Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nocturnal Enuresis Medication Market

• 26.1. South America Nocturnal Enuresis Medication Market Overview
• 26.2. South America Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nocturnal Enuresis Medication Market

• 27.1. Brazil Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nocturnal Enuresis Medication Market

• 28.1. Middle East Nocturnal Enuresis Medication Market Overview
• 28.2. Middle East Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nocturnal Enuresis Medication Market

• 29.1. Africa Nocturnal Enuresis Medication Market Overview
• 29.2. Africa Nocturnal Enuresis Medication Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nocturnal Enuresis Medication Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nocturnal Enuresis Medication Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nocturnal Enuresis Medication Market Competitive Landscape And Company Profiles

• 30.1. Nocturnal Enuresis Medication Market Competitive Landscape
• 30.2. Nocturnal Enuresis Medication Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Dr. Willmar Schwabe GmbH & Co. KG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Ferring Pharmaceuticals A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. UroGen Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Nocturnal Enuresis Medication Market Other Major And Innovative Companies

• 31.1. Bakson Drugs and Pharmaceuticals Pvt. Ltd.
• 31.2. Nordic Pharma Group
• 31.3. Dr. Reckeweg & Co. GmbH
• 31.4. Chummie
• 31.5. Taiho Pharmaceutical Co. Ltd.
• 31.6. AA Pharma Inc.
• 31.7. Bakson Drugs and Pharmaceuticals Pvt. Ltd.
• 31.8. Aark Pharmaceuticals Ltd.
• 31.9. Alturix Ltd.
• 31.10. Wellesley Pharmaceuticals LLC
• 31.11. German Homoeo Care and Cure Pvt. Ltd.
• 31.12. Laboratoires Ledoux Reflexe Inc.
• 31.13. Global Continence Inc.
• 31.14. Serenity Pharmaceuticals LLC
• 31.15. Vantia Therapeutics Ltd.

32. Global Nocturnal Enuresis Medication Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nocturnal Enuresis Medication Market

34. Recent Developments In The Nocturnal Enuresis Medication Market

35. Nocturnal Enuresis Medication Market High Potential Countries, Segments and Strategies

• 35.1 Nocturnal Enuresis Medication Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nocturnal Enuresis Medication Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nocturnal Enuresis Medication Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer